Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (685)	6/19/2003 12:15:51 PM
From: Icebrg	Respond to of 2240

>>Sorry if this is repeat.>> No, it wasn't. Thanks for posting. Do you have any opinion if the recorded results may be considered as good, bad or just so-so?

To: keokalani'nui who wrote (685)	6/19/2003 12:24:01 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 2240

It's small trial, P1 etc. etc. This part sounds pretty good: >>In a pooled analysis of all dose cohorts, ACR20 response (from week 0) was achieved in 15 of 24 patients (63%), ACR50 in 38% and ACR70 in 25%.<< But these aspects don't: --infusion --pts not on other DMARDS, so comparison looks better than in practice --single loading dose and 4 subsequent weekly doses doesn't sound like it would be popular Have no idea whether anti-IL-15 would serve an unserved market.